Sector
PharmaceuticalsOpen
₹50.95Prev. Close
₹49.96Turnover(Lac.)
₹0.27Day's High
₹50.95Day's Low
₹5052 Week's High
₹69.552 Week's Low
₹43.75Book Value
₹43.49Face Value
₹10Mkt Cap (₹ Cr.)
48.79P/E
31.56EPS
1.6Divi. Yield
0Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 9.66 | 9.66 | 9.25 | 8.82 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 30.93 | 29.58 | 27.22 | 24.67 |
Net Worth | 40.59 | 39.24 | 36.47 | 33.49 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Revenue | 58.75 | 48.36 | 49.01 | 42.82 |
yoy growth (%) | 21.47 | -1.32 | 14.45 | 4.25 |
Raw materials | -34.5 | -25.11 | -28.39 | -25.63 |
As % of sales | 58.71 | 51.92 | 57.92 | 59.86 |
Employee costs | -8.01 | -6.85 | -5.93 | -5.41 |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Profit before tax | 1.68 | 0.92 | 0.75 | -0.03 |
Depreciation | -0.55 | -0.55 | -0.6 | -0.86 |
Tax paid | -0.58 | -0.19 | -0.19 | -0.49 |
Working capital | 5.71 | -2.3 | -5.65 | -2.17 |
Other operating items |
Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 21.47 | -1.32 | 14.45 | 4.25 |
Op profit growth | 48.33 | -40.99 | 33.22 | -36.08 |
EBIT growth | 32.42 | -31.72 | 36.55 | -38.08 |
Net profit growth | 51.66 | 28.27 | -226.4 | -182.58 |
Particulars (Rupees in Crores.) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 |
---|---|---|---|---|
Gross Sales | 67.19 | 67.28 | 65.35 | 65.5 |
Excise Duty | 0 | 0 | 0 | 0 |
Net Sales | 67.19 | 67.28 | 65.35 | 65.5 |
Other Operating Income | 0 | 0 | 0 | 0 |
Other Income | 0.17 | 0.42 | 0.33 | 0.08 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,647.35 | 92.29 | 3,95,254.45 | 2,000.46 | 0.97 | 7,107.14 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,493.2 | 78.03 | 1,72,374.06 | 667 | 0.46 | 2,536 | 561.08 |
Cipla Ltd CIPLA | 1,483.15 | 24.33 | 1,19,795.19 | 1,485.4 | 1.08 | 4,254.47 | 397.41 |
Dr Reddys Laboratories Ltd DRREDDY | 1,326.4 | 20.69 | 1,10,689.83 | 1,200.7 | 0.6 | 5,546.3 | 345.79 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,167.95 | 56.27 | 1,07,213.01 | 474 | 1.01 | 2,385 | 224.33 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Non-Exec & Non-Independent Dir
Shashank B Sandu
Managing Director
Umesh B Sandu
Company Sec. & Compli. Officer
Pratika Mhambray
Independent Director
Vijay Kottapalli
Non Executive Director
Jayshree Sandu
Chairman & Independent Directo
Balaram Vishwanathan
Independent Director
Ajit Rajaram Kantak
Plot No 25/26/29 & 30,
Pilerne Indl Estate Marra Bard,
Goa - 403511
Tel: -
Website: http://www.sandu.in
Email: corp.sec@sandu.in
C-101 247 Park,
L B S Marg, Vikhroli West,
Mumbai - 400083
Tel: 91-22-28515644/5606
Website: www.sharexindia.com
Email: support@sharexindia.com
Summary
Sandu Pharmaceuticals Ltd (SPL) was established in 1985. The Company is mainly engaged in the business of manufacturing and trading of Ayurvedic medicines under the brand name SANDU.SPL came out with ...
Read More
Reports by Sandu Pharmaceuticals Ltd
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.